Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

X
Trial Profile

A Phase I Study of Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omburtamab-I-124 (Primary) ; Liothyronine; Potassium iodide
  • Indications Brain cancer; Glioma
  • Focus Adverse reactions; First in man
  • Sponsors Y-mAbs Therapeutics
  • Most Recent Events

    • 25 May 2022 Status changed from discontinued to completed.
    • 07 Feb 2022 Status changed from recruiting to discontinued as stopping rule was met per protocol as a result of the last two subjects experiencing dose limiting toxicities
    • 08 Jun 2021 Results (n=46) assessing the safety of administering escalating doses and volumes of 124I-omburtamab by convection-enhanced delivery in children with diffuse intrinsic pontine glioma, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top